DaraPay Announces Strategic Partnership with Chinese Tech Giant- Alipay
18.11.2019 06:26:00 EET | Business Wire | Press release
DaraPay, the leading mobile E-wallet and payment service providers, today announces its partnership with Alipay, world’s leading payment and lifestyle platform operated by Ant Financial. With this partnership, Chinese tourists can scan and pay with their Alipay app at all DaraPay merchants with more than 3,000 outlets in Phnom Penh, Kandal, Kampong Cham, Siem Reap and Battambang province.
Alipay serves over 1.2 billion users together with its regional partners and is the preferred payment method of Chinese tourists1.
Through this strategic partnership, the two partners are looking to integrate their respective systems with one another and offer the market a flexible, on-demand digital payment solution through which Chinese tourists can conveniently use during their visit to Cambodia.
With the system now in place, Alipay users are no longer required to withdraw cash or perform cross-app money transfer to make payments across the Kingdom. They can simply complete their purchases by scanning the special QR code available at DaraPay-enabled merchant partners.
“We are excited to work with Alipay,” said Mr. Phok Ratha, General Manager of DaraPay. “Through this collaboration, Alipay users can now benefit from the convenience, simplicity, and security of our integrated system and merchant partners while enjoying their vacation in Cambodia.”
With DaraPay's more than 3,000 merchant partners, finding a store or service that accepts this integrated mobile payment should not be a trouble. Whether it is a transaction at a restaurant, café, and supermarket or payment for services such as ride-hailing, hotel, and entertainments, Chinese tourists can truly benefit by choosing the services of DaraPay’s merchant partners. Alipay customers who love shopping for apparel or trying out all types of delicious food can enjoy with the most popular Chinese tourist malls: Sorya Center Point or The Olympia Mall located at the heart of Phnom Penh City.
The future bodes well for the two partners with the number of Chinese tourists visiting the Kingdom continues to grow. Last year, statistically the nation welcomed over 1.7 million Chinese tourists, and the number is expected to rise to 3 million by 2020 and 5 million by 2025.
As the number of Chinese tourists to the Kingdom continues to surge, and following its strategic road map, DaraPay is on track with its collaboration with leading fintech platform Alipay.
Mr. Ratha continued, "The partnership with Alipay is an important step that takes DaraPay to the next level of our business development. We do not only collaborate with local businesses but we are also actively working with international partners as part of our new strategic roadmap to enter a new horizon. In the future, we are looking to collaborate with other international partners to bring better and more innovative services to cater to our customers both the locals and international ones.”
About DaraPay:
DaraPay is a trademark of CANADIA-FULLERTON MOBILE MONEY PLC., a corporation duly established in 2016. DaraPay is a joint venture between Canadia Investment Holding (CIH) of Cambodia and Fullerton Financial Capital (FFC), a subsidiary of Fullerton Financial Holdings (FHH) of Singapore, for the purpose of operating a mobile wallet and payments business in Cambodia. DaraPay’s services include Local Money Remittance, Cash-In / Cash Out, Utilities Bill Payments, Phone Top Up, Bill Payment, E-commerce Payment, Merchant Payment, Loan Repayment, Loan Referral, Payroll service, Mobile Wallet and other financial related products. As of August 2019, DaraPay has more than 4,500 agents nationwide and has more than 3,000 merchants available to accept the payment. Through DaraPay, thousands of people and families in both provinces and urban cities are sending money anywhere, any time at the peace of mind.
Don’t have DaraPay App yet?
Android & iOS users, download now:
https://goo.gl/7tvY1E
DaraPay: Fast, Secure and Everywhere.
About Alipay:
Operated by Ant Financial Services Group, Alipay is the world’s leading payment and lifestyle platform. Launched in 2004, Alipay serves over 1.2 billion users with its local e-wallets partners as of June 2019. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Alipay’s in-store payment service covers over 50 markets across the world, and tax reimbursement via Alipay is supported in 35 markets. Alipay currently supports 27 currencies, and works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191117005080/en/
Contact information
For media inquiry:
Mr. Phok Ratha, General Manager, CANADIA-FULLERTON MOBILE MONEY PLC.
Tel: +855 81 799 888
Email: ratha.phok@darapay.com.kh
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom